Neuropathological Examination

Introduction

Neuropathological Examination is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Introduction

Neuropathological Examination is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Neuropathological examination — the systematic gross and microscopic analysis of brain tissue, typically obtained at autopsy — remains the definitive gold standard for diagnosing most neurodegenerative diseases ([Dickson, 2012](https://pubmed.ncbi.nlm.nih.gov/22451012/)). Despite major advances in fluid biomarkers ([csf-biomarkers](/diagnostics/csf-biomarkers), [plasma-biomarkers](/diagnostics/plasma-biomarkers) and [neuroimaging](/diagnostics/neuroimaging) including [pet-imaging](/diagnostics/pet-imaging), no combination of in vivo tests can yet match the diagnostic specificity achieved by direct visualization of pathological protein deposits, cellular changes, and regional patterns of neurodegeneration in tissue. Neuropathological examination has shaped our understanding of every major neurodegenerative disease — defining the [Amyloid-Beta](/proteins/amyloid-beta) plaques and [tau](/proteins/tau)[/proteins/[tau-protein](/proteins/tau) tangles of [alzheimers](/diseases/alzheimers-disease), the Lewy bodies of [parkinsons](/diseases/parkinsons-disease), the [tdp-43](/proteins/tdp-43) inclusions of [als](/diseases/als)-[ftd](/diseases/frontotemporal-dementia), and the prion plaques of [creutzfeldt-jakob](/diseases/creutzfeldt-jakob). It continues to reveal new pathological entities and co-pathologies that inform our understanding of neurodegeneration and validate emerging biomarkers. [@refa]

The Neuropathological Examination Process

Brain Procurement and Fixation

Gross Examination

The macroscopic examination reveals patterns of atrophy that suggest specific diagnoses: [@refb]

| Disease | Gross Findings | [@refc]
|---------|---------------| [@refd]
| [alzheimers](/diseases/alzheimers-disease) | Diffuse cortical atrophy (temporal > frontal > parietal), widened sulci, hippocampal atrophy, ventricular dilation | [@refe]
| [ftd](/diseases/frontotemporal-dementia) | Frontal and/or anterior temporal lobe atrophy (often asymmetric); "knife-edge" gyri | [@reff]
| [parkinsons](/diseases/parkinsons-disease) | Pallor of [substantia-nigra](/brain-regions/substantia-nigra) and [locus-coeruleus](/brain-regions/locus-coeruleus) (loss of neuromelanin pigmentation) | [@refg]
| [huntington-pathway](/mechanisms/huntington-pathway) | Severe caudate nucleus and putamen ([striatum](/brain-regions/striatum) atrophy; ex vacuo ventricular dilation | [@refh]
| [als](/diseases/amyotrophic-lateral-sclerosis) | Often grossly unremarkable brain; [motor-cortex](/brain-regions/motor-cortex) atrophy in some cases; [spinal-cord](/brain-regions/spinal-cord) thinning | [@refi]
| [creutzfeldt-jakob](/diseases/creutzfeldt-jakob) | Cortical spongiform change; rapid brain atrophy |
| [msa](/diseases/msa-genetic-variants) | Putaminal atrophy; cerebellar and pontine atrophy (olivopontocerebellar type) |

Histological Staining

Standard tissue processing involves paraffin embedding, sectioning (4-8 um), and staining:

Routine stains:

• Hematoxylin and eosin (H&E): Basic morphology; reveals neuronal loss, gliosis, spongiform change, inflammation
• Luxol fast blue (LFB): Myelin staining; detects [demyelination](/mechanisms/demyelination) in white matter
• Congo red / Thioflavin-S: Amyloid detection under polarized light (Congo red) or fluorescence (Thioflavin-S)
• Silver stains (Bielschowsky, Gallyas): Classic techniques for detecting neurofibrillary tangles and senile plaques

| Antibody | Target | Disease Association |
|----------|--------|-------------------|
| Anti-[amyloid-beta](/proteins/amyloid-beta) (4G8, 6E10) | [Amyloid-Beta](/proteins/amyloid-beta) plaques | [alzheimers](/diseases/alzheimers-disease), CAA |
| Anti-phospho-tau] (AT8, PHF-1) | Hyperphosphorylated [tau](/proteins/tau) | AD, [psp](/diseases/progressive-supranuclear-palsy), [corticobasal-degeneration](/diseases/corticobasal-degeneration), FTLD-[tau](/proteins/tau) |
| Anti-[alpha-synuclein](/proteins/alpha-synuclein) | [alpha-synuclein](/proteins/alpha-synuclein) aggregates | PD, DLB, [msa](/diseases/msa-genetic-variants) |
| Anti-[tdp-43](/proteins/tdp-43) (phospho) | [tdp-43](/proteins/tdp-43) inclusions | [als](/diseases/amyotrophic-lateral-sclerosis), FTLD-TDP, [late](/diseases/late) |
| Anti-FUS | [fus-protein](/proteins/fus-protein) inclusions | FTLD-FUS, ALS-FUS |
| Anti-p62/SQSTM1 | [p62-sqstm1](/proteins/p62-sqstm1) inclusions | Pan-neurodegenerative marker |
| Anti-ubiquitin | Ubiquitinated inclusions | Non-specific; identifies protein aggregates |
| Anti-prion protein | [prion-protein](/proteins/prion-protein) deposits | [creutzfeldt-jakob](/diseases/creutzfeldt-jakob), [gss](/diseases/gss) |
| Anti-[huntingtin](/proteins/huntingtin) (polyQ) | [huntingtin](/proteins/huntingtin) aggregates | [huntington-pathway](/mechanisms/huntington-pathway) |
| [glial-fibrillary-acidic-protein](/entities/glial-fibrillary-acidic-protein) | Reactive [astrocytes](/cell-types/astrocytes) | Gliosis marker (non-specific) |
| Iba1 | [microglia](/cell-types/microglia)/cell-types/microglia | [neuroinflammation](/mechanisms/neuroinflammation) marker |

Pathological Staging Systems

Standardized staging systems enable systematic classification of disease severity:

Alzheimer's Disease: NIA-AA Criteria

The NIA-AA neuropathological criteria assess three features using the "ABC" score ([Montine et al., 2012](https://pubmed.ncbi.nlm.nih.gov/22218222/)):

• A: Amyloid plaque score (Thal phases 0-5): Measures the anatomical spread of [amyloid-beta](/proteins/amyloid-beta) deposits, from isocortex (phase 1) through allocortex, diencephalon, brainstem, to [cerebellum](/brain-regions/cerebellum) (phase 5)
• B: [braak-staging](/mechanisms/braak-staging) (stages 0-VI): Maps the progression of neurofibrillary tau] pathology from [entorhinal-cortex](/brain-regions/entorhinal-cortex) (I-II) through [hippocampus](/brain-regions/hippocampus) (III-IV) to neocortex (V-VI)
• C: CERAD neuritic plaque score (none, sparse, moderate, frequent): Semi-quantitative assessment of neuritic plaque density in neocortex

Parkinson's Disease: Braak Staging (alpha-synuclein)

The Braak staging system for Lewy body pathology describes caudal-to-rostral progression ([Braak et al., 2003](https://pubmed.ncbi.nlm.nih.gov/12498954/)):

• Stage 1-2: [olfactory-bulb](/brain-regions/olfactory-bulb), dorsal motor nucleus of vagus, [locus-coeruleus](/brain-regions/locus-coeruleus)
• Stage 3-4: [substantia-nigra](/brain-regions/substantia-nigra), [amygdala](/brain-regions/amygdala), basal forebrain
• Stage 5-6: Neocortical spread ([cingulate-cortex](/brain-regions/cingulate-cortex), temporal, frontal, parietal)

FTLD Classification

FTLD is classified by the predominant protein pathology ([Mackenzie et al., 2010](https://pubmed.ncbi.nlm.nih.gov/19826947/)):

• FTLD-tau]: Includes [psp](/diseases/progressive-supranuclear-palsy), [corticobasal-degeneration](/diseases/corticobasal-degeneration), [pick-disease](/diseases/pick-disease), and other 3R/4R tauopathies
• FTLD-TDP: Types A-E based on [tdp-43](/proteins/tdp-43) inclusion morphology and distribution
• FTLD-FUS: Rare; includes atypical FTLD-U, NIFID, and BIBD
• FTLD-[UPS](/mechanisms/ubiquitin-proteasome-system): Very rare; ubiquitin-positive, [tdp-43](/proteins/tdp-43)/FUS-negative

ALS Staging

[tdp-43](/proteins/tdp-43) pathology in ALS follows a four-stage spread pattern from the [motor-cortex](/brain-regions/motor-cortex) and [spinal-cord](/brain-regions/spinal-cord) motor [neurons](/entities/neurons) (stage 1) through [prefrontal-cortex](/brain-regions/prefrontal-cortex) and brainstem reticular formation (stage 2-3) to [hippocampus](/brain-regions/hippocampus) and temporal [cortex](/brain-regions/cortex) (stage 4) ([Brettschneider et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23474848/)).

Co-Pathologies and Mixed Dementias

One of the most important contributions of neuropathological examination is revealing the high prevalence of co-occurring pathologies:

• AD + Lewy body pathology: Up to 50% of AD cases at autopsy have concomitant alpha
• AD + vascular pathology: Small vessel disease, microinfarcts, and cerebral amyloid angiopathy are common in AD brains
• AD + [late](/diseases/late): Limbic-predominant age-related [tdp-43](/proteins/tdp-43) encephalopathy affects 20-50% of individuals over 80, often co-occurring with AD
• AD + hippocampal sclerosis: Present in ~10% of dementia cases over 85
• Multiple co-pathologies: Many dementia cases, particularly in the oldest-old (>90), show 3+ concurrent pathologies

Modern Techniques

Digital Neuropathology

Whole slide imaging (WSI) and computational pathology are transforming neuropathological practice:

• Automated quantification: Machine learning algorithms quantify plaque density, tangle counts, and inclusion burden more reproducibly than manual semi-quantitative ratings
• Spatial transcriptomics: Combining histology with spatial gene expression profiling to understand cell-type-specific vulnerability
• Deep learning: Neural networks trained to classify neurodegenerative pathology approaching expert-level accuracy

Molecular Neuropathology

• Cryo-electron microscopy: Reveals the ultrastructure of pathological protein filaments (tau], [alpha-synuclein](/proteins/alpha-synuclein), TDP-43), distinguishing disease-specific conformational strains
• Mass spectrometry proteomics: Identifies protein compositions of inclusions and post-translational modifications
• Single-nucleus RNA sequencing: Applied to fresh-frozen tissue to profile gene expression changes in specific cell types affected by neurodegeneration

Clinical-Pathological Correlation

Neuropathological examination enables critical clinicopathological correlations:

• Diagnostic accuracy validation: Clinical diagnosis accuracy for AD is ~70-90%, improving to ~95% with [biomarkers](/biomarkers). Neuropathology reveals the true diagnosis
• Biomarker validation: Every new imaging or fluid biomarker must be validated against neuropathological ground truth
• Treatment response assessment: Post-mortem examination of participants in clinical trials reveals whether treatments reduced target pathology (e.g., anti-amyloid antibody trials showing plaque clearance)
• Discovery of new entities: Neuropathology has identified novel conditions including [late](/diseases/late), [argyrophilic-grain-disease](/diseases/argyrophilic-grain-disease), and [primary-age-related-tauopathy](/diseases/primary-age-related-tauopathy) (PART)

Brain Banks and Donation Programs

Major brain bank networks support neuropathological research:

• NIH NeuroBioBank: Coordinating network of brain repositories across the United States
• Brain Bank Network (BrainNet Europe): European consortium standardizing neuropathological protocols
• UK Brain Banks Network: Eight brain banks across the United Kingdom
• Mayo Clinic Brain Bank: Major repository for neurodegenerative disease cases
• ADNI (Alzheimer's Disease Neuroimaging Initiative): Collects post-mortem data from study participants

See Also

• [csf-biomarkers](/diagnostics/csf-biomarkers)
• [neuroimaging](/diagnostics/neuroimaging)
• [pet-imaging](/diagnostics/pet-imaging)

External Links

• [NIA-AA Neuropathological Criteria for AD](https://pubmed.ncbi.nlm.nih.gov/22218222/)
• [BrainNet Europe Consortium](https://www.brainnet-europe.org)
• [NIH NeuroBioBank](https://neurobiobank.nih.gov)

Background

The study of Neuropathological Examination has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References